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Abstract: Diabetes mellitus (DM), and its micro and macrovascular complications, is one of the
biggest challenges for world public health. Despite overall improvement in prevention, diagnosis and
treatment, its incidence is expected to continue increasing over the next years. Nowadays, finding
therapies to prevent or retard the progression of diabetic complications remains an unmet need
due to the complexity of mechanisms involved, which include inflammation, oxidative stress and
angiogenesis, among others. Flavonoids are natural antioxidant compounds that have been shown
to possess anti-diabetic properties. Moreover, increasing scientific evidence has demonstrated their
potential anti-inflammatory and anti-oxidant effects. Consequently, the use of these compounds
as anti-diabetic drugs has generated growing interest, as is reflected in the numerous in vitro
and in vivo studies related to this field. Therefore, the aim of this review is to assess the recent
pre-clinical and clinical research about the potential effect of flavonoids in the amelioration of diabetic
complications. In brief, we provide updated information concerning the discrepancy between the
numerous experimental studies supporting the efficacy of flavonoids on diabetic complications and
the lack of appropriate and well-designed clinical trials. Due to the well-described beneficial effects
on different mechanisms involved in diabetic complications, the excellent tolerability and low cost,
future randomized controlled studies with compounds that have adequate bioavailability should be
evaluated as add-on therapy on well-established anti-diabetic drugs.
Keywords: flavonoids; diabetes; microvascular complications; cardiovascular disease; diabetic
nephropathy; oxidative stress; inflammation; therapeutics
1. Introduction
Diabetes mellitus (DM) is currently one of the greatest public health challenges in the world.
Despite the new tools of control and prevention for early diagnosis, its prevalence is still increasing.
Successive reports generated by the International Diabetes Federation have shown the increasing
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incidence of people with DM (actually 463 million adults) and the estimated projection for the year
2045 will rise to 700 million people affected [1].
It has been estimated that one out of every two individuals with DM is not aware of having
the disease. This is particularly important in patients with type 2 diabetes (T2D) due to the long
asymptomatic phase, which increases the risk of microvascular and macrovascular complications, the
risk of death compared with normoglycemic individuals, and the tremendous economic cost for the
health system [1–4]
The incidence of diabetes-related complications has declined substantially in the past decades
worldwide probably due to a substantial improvement in preventive care programs for adults with
diabetes and the extensive use of drugs controlling blood glucose, hypertension and dyslipidemia,
among others [5]. However, a large burden of disease persists because of the continued increase in
the prevalence of diabetes, mainly due to the threats of increasing obesity, world overpopulation and
aging [6,7].
Although the recent availability of novel anti-diabetic drugs (e.g., incretin modulators and
sodium-glucose transport protein-2 inhibitors) will certainly further decrease the rates of cardiovascular
risk and mortality in diabetic patients, the research for new drugs to halt the progression of diabetic
complications is still necessary [8–11]. Due to the complexity of the pathogenic mechanisms
driving long-term complications of diabetes, including inflammation and oxidative stress, the clinical
introduction of novel drugs combating those conditions would be of interest [12].
In this review, we have focused on the potential beneficial effects of flavonoids on different
mechanisms involved in diabetic complication, as well as the current state of research related to
the preclinical and clinical usefulness of these compounds in this clinical condition. On the whole,
we provide information supporting the future development of well-designed clinical trials with
flavonoids that have adequate bioavailability as add-on therapy on well-established anti-diabetic drugs.
2. Pathogenesis of Diabetic Complications
DM is associated with several chronic complications, mainly classified as macrovascular and
microvascular complications. Among them, coronary artery disease, peripheral arterial disease and
stroke are described as macrovascular complications, due to a close relationship with atherosclerotic
mechanisms. On the other hand, diabetic microangiopathies or microvascular complications are
described at the ocular (retinopathy), renal (nephropathy) and peripheral nerve (neuropathy) levels,
and are characterized by changes in the thickness of the capillary basement membrane [13,14].
In the genesis of the diabetic complications, hyperglycemia is the driving force for clinical features,
which in synergy with other risk factors (hypertension, obesity, dyslipidemia) potentiates and accelerates
the histopathological features classically observed in each of the tissue-specific manifestations of the
DM [15,16]. Simultaneously, as a consequence of hyperglycemia, alterations in signaling and glucose
metabolism are observed, promoting insulin resistance in target organs and beta cell dysfunction [17].
The influence of the genetic background as an individual risk factor is not only important in
type 1 diabetes (T1D), but rather in all tissue-specific manifestations of DM [18]. The analyses of
multicenter population genetic studies and genome-wide association studies (GWASs) have reported
certain risk polymorphisms (single-nucleotide polymorphisms—SNPs) that could be involved in
the diverse pathogenesis of complications associated with DM [19]. The proposed actions for these
SNPs are related to phagocytosis, cytoskeleton rearrangement, fibroblast migration and lymphocyte
infiltration [20]. Other studies have suggested the influence of gene alterations associated with
transport and glucose metabolism, the renin angiotensin aldosterone system (RAAS), transcription
factors and growth factors [21,22].
The maintenance of a hyperglycemic state involves the anabolic-catabolic production of toxic
metabolites, which activate metabolic and hemodynamic pathways through the formation of advanced
glycation end products (AGEs), activation of protein kinase C (PKC) and polyol sorbitol pathway,
activation of RAAS, vascular endothelial growth factor A (VEGFA) and endothelin-1 and receptor type
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A (ET1/ETA). These processes cause remodeling in the architecture of the different target organs and
ultimately atrophic changes [23–26]. On the other hand, the presence of oxidative stress and altered
redox homeostasis in resident cells are characteristics commonly observed in DM patients [27–29].
Uncoupling endothelial nitric oxide synthase (eNOS) and the bioavailability of nitric oxide (NO) are
two main factors responsible for the changes of vascular reactivity and production of reactive oxygen
and nitrogen species (ROS/RNS) [30–32]. Additionally, dysregulation between pro-oxidant enzymes
(e.g., NADPH oxidase complex (Nox), xanthine oxidase, cytochrome 450 and myeloperoxidase) and
antioxidant enzymes (e.g., superoxide dismutase, glutathione peroxidase and catalase) is a major
contributor to redox imbalance [33–35].
Kinases and transcription factors involved in many inflammatory and oxidative stress responses,
activate intracellular signaling pathways that lead to the production of pro-inflammatory, pro-oxidant
and pro-angiogenic factors such as cytokines, chemokines, pro-oxidant enzymes, growth factors,
adhesion molecules and extracellular matrix proteins, among others [36–40].
Chronic hyperglycemia is the main pathogenic factor involved in DM complications, mainly
triggering systemic and local microinflammation and therefore an important therapeutic target to
hamper the development and progression of diabetic complications [41].
3. General Aspects of Flavonoids
Flavonoids are an important class of natural products; more precisely, flavonoids are one of the
largest groups of plant secondary metabolites, comprising at least 6000 phenolic compounds. They are
widely found in fruits, vegetables, nuts, grain seeds, cocoa, chocolate, tea, soy, red wine, herbs and
beverage products [42–45].
Flavonoids share a common chemical structure (Figure 1A) based on a C6-C3-C6 skeleton, where
two aromatic rings are linked by a three-carbon chain that forms an oxygenated heterocyclic ring [42–44].
Depending on the degree of unsaturation and the substitution pattern, different flavonoid classes can
be distinguished (Figure 1B): flavones, flavonols, flavanones, flavan-3-ols, anthocyanins, dihydroflavonols,
and isoflavones, as well as the biogenetic intermediate chalconoid forms [43].
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described in th literature.
Flavonoids have long bee sed in traditional medicine mainly due to their antioxidant properties;
for example, Radix Puerariae ( in) has been used to tr at diabetes for housands of years. Flavonoids
are associated with a broad spectrum of health-promoting effects because of their anti-oxidative,
anti-inflammatory and anti-carcinogenic properties and their capacity to modulate key cellular enzyme
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functions [46]. Nowadays, flavonoids are present in the pharmaceutical market in different formats
such as tablets, hard capsules, granules, oral solutions and gel. The main commercialized flavonoids
(Diosmin, Hesperidin, Troxerutin and Hidrosmin) are mostly used for the treatment of edema and venous
insufficiency [47].
4. Recent Preclinical Advances in the Anti-Diabetic Actions of Flavonoids
The anti-inflammatory, anti-oxidant and anti-hyperlipidemic effects of flavonoids have been widely
demonstrated. For this reason, there is much interest in these compounds as potential anti-diabetic
drugs. This is reflected in the large number of in vitro and in vivo studies carried out to assess the
effect of flavonoids in the context of diabetes [48–50].
Flavonoids modulate glucose metabolism or insulin sensitivity at different levels, increasing
glucose uptake and insulin secretion, and inhibiting glucose production [51]. There are several
publications describing the anti-diabetic action of flavonoids on different tissues such as skeletal
muscle, white adipose tissue, liver, small intestine, pancreas and kidney [52]. In skeletal muscle and
white adipose tissue, flavonoids mainly act on glucose transporter type 4 (GLUT4), increasing its
translocation to the plasma membrane allowing the uptake of glucose from blood. The translocation
of GLUT4 can be mediated by activation of different pathways such as phosphoinositide 3-kinase
(PI3K)/protein kinase B (Akt) [53], and AMP-activated protein kinase (AMPK) [54]. In skeletal muscle,
Yamashita et al. demonstrated that liquorice flavonoid oil promoted GLUT4 translocation by activation
of the AMPK pathway and improved symptoms in T2D [54]. Sea buckthorn extract, rich in quercetin,
isorhamnetin and gallic acid, also stimulated GLUT4 translocation in adipocytes and improved glucose
uptake activity [53].
On the other hand, some flavonoids act by inhibiting the expression or translocation of GLUT2).
In liver, Baicalin reduces GLUT2 in addition to other gluconeogenic genes, such as glucose-6-phosphatase
(G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK), therefore inhibiting the synthesis of
glucose and its subsequent release into the bloodstream [55]. The production of hepatic glucose is also
inhibited by other flavonoids such as epigallocatechin gallate, that acts by reducing the expression of
PEPCK and G6Pase in hepatic (HepG2) cells [56,57] and xanthohumol, that inhibits GLUT2 expression
in the liver of diabetic rats [58]. The reduction of GLUT2 was noted, not only in liver but also in
human intestinal cells, by the administration of anthocyanin-rich berry extract [59], myricetin, fisetin and
quercetin [60].
An effective strategy to reduce increased glucose levels (in postprandial hyperglycemia,
for example) is to retard the intestinal digestion of complex carbohydrates through the inhibition
of α-glucosidases. In this sense, flavonols such as rutin, quercetin and isoquercetin are considered
α-glucosidase inhibitors. The inhibition of α-glucosidase prevents glucose absorption and consequently
reduces postprandial blood glucose levels in the Sprague–Dawley rat model [61].
Another beneficial effect that flavonoids exert is the preservation of β-cell viability by reducing
inflammation and oxidative damage. The capacity of guava leaf extract (containing anthocyanins
and quercetin) to increase the pancreatic levels of different antioxidant enzymes such as superoxide
dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) and to downregulate the expression
of inflammatory mediators, such as TNF-α and IL-6, in streptozotocin (STZ)-induced diabetic rats has
been demonstrated [62]. Naringin also has a protective effect on β-cells due to its capacity to prevent
apoptosis through the inhibition of both the intrinsic (mitochondria-mediated) and extrinsic (death
receptor-mediated) pathways. These anti-apoptotic effects are associated with a reduction in ROS and
inflammatory cytokines [63].
In summary, flavonoids exert their anti-diabetic effects in part by acting on different tissues
(pancreas, liver, adipose tissue and skeletal muscle) involved in the modulation of glucose homeostasis
and insulin sensitivity (Figure 2).
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5. Current Status of Experimental Research on Flavonoids in Chronic Complications of Diabetes
Due to the potent antioxidant effect of flavonoids, the therapeutic potential of these compounds
has been evaluated in several chronic diseases including cancer, neurodegenerative and cardiovascular
disorders, and diabetes. Thus, the present review focuses on the most recent (last 3 years) preclinical
studies of flavonoids for the treatment of microvascular (nephropathy, retinopathy and neuropathy)
and macrovascular (cardiovascular) complications of diabetes (Table 1).
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Table 1. Effects and Mechanisms of Action of Flavonoids on Chronic Complications of DM. In vivo and in vitro Experiments.
In vivo Studies
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Mouse T2D db/db mouse Chrysin 10 mg/kg/day10 weeks
↓ Collagen fiber accumulation
↓ AGEs accumulation Anti-fibrotic 29987200
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Table 1. Cont.
In vivo Studies
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In vivo Studies
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↑Nrf2; ↓ caspase-3 in neurons





Rat T1D STZ Resveratrol 10 mg/kg/day120 days
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Rat T2D HGI Rutin 25–50 mg/kg/day12 weeks
↓ inflammasome pathway in
aortic tissue; ↓ROS generation
Anti-inflammatory
and anti-oxidant 27936392
















Rat T1D STZ + IRIA
Resveratrol 5 mg/kg/day +
Glibenclamide 5 mg/kg/day
6 weeks
↑ Kir6.2 expression (subunit
of KATP channel)
Anti-arrhythmic 28176247
Rat T1D STZ Heracleum Persicum100 mg/kg/day; 8 weeks ↓MDA; ↑GSH, CAT and SOD Anti-oxidant 29726706
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Table 1. Cont.
In vivo Studies
Disease Animal DM Model Treatment Results Effect PMID
Rat T1D STZ Isoquecertin 40 mg/kg/day45 days ↓ TG, PPL and FFA Anti-hyperlipidemic 30817903
Rat T1D STZ Galangin 40 mg/kg45 days
↓ TG, PPL, total cholesterol
and FFA Anti-hyperlipidemic 29952676
Mouse T2D db/db mouse Scutellarin 25–100 mg/kg8 weeks
↑ high-density lipoprotein
cholesterol
↓ TG and cholesterol
Anti-hyperlipidemic 30881587






Mouse T2D HFI Liquiritin10/20 mg/kg/day ↓α-SMA, Col I and Col II Anti-fibrotic 27810791
In vitro Studies
















Hydrogen peroxide and nitric
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Rat mesangial cells HG Marein 100–400 µM
Regulating AMPK,
TGF-β1/Smads pathway









Mesangial cells HG Corn silk extract200 µg/mL
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Rat mesangial cells AGEs Kaempferitrin 10–35 µM ↑SOD activity
↓MDA, Col IV and TGF-β1
Anti-oxidant and
anti-fibrotic 30373106
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Table 1. Cont.
In vitro Studies
Disease Cell type Stimulus Treatment Results Effect PMID
Rat mesangial cells HG Liquiritigenin 20–40 µM
↓ NOX4 and ↑SOD
Decrease collagen IV










line HG Genistein 20 µM Inactivating mTOR signaling Autophagia 29999001
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Modulating NLRP3 signaling
pathway
↓IL-1β, IL-18 and caspase-1
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and anti-apoptotic 29929501
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↓MDA levels; ↑SOD and ROS
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Table 1. Cont.
In vitro Studies
Disease Cell type Stimulus Treatment Results Effect PMID
Human retinal pigment
epithelium cells HG Chrysin 1–20 µM
↓VEGF and PDGF, AGEs





↑CAT, SOD, ↓ Nox4 and
eNOS levels





Rat retinal ganglial cells HG Eriodictyol5–20 µM





































ganglion neurons HG Quercetin 2.5–10 mmol/L


























vein endothelial cells HG Rutin 30–100 µM ↓Nox2 and Nox4 Anti-oxidant 27936392
Human aortic
endothelial cells Palmitic acid Resveratrol 50–100 µM
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5.1. Diabetic Nephropathy
Diabetic nephropathy (DN), one of the most prevalent complications in diabetes, is characterized
by a progressive development of renal dysfunction. In the early stage, the first symptom is
microalbuminuria (appearance of low levels of albumin in the urine, 30–300 mg/g), which precedes
macroalbuminuria (high levels of albumin in the urine, >300 mg/g), leading to a deterioration of
renal function and progression to End Stage Renal Disease (ESRD) [64]. Accumulating evidence has
clearly demonstrated that immune-inflammatory response plays a paramount role in the onset and
progression of diabetic kidney disease. This process is mediated by elements of the immune system
(e.g., lymphocytes and monocytes/macrophages) and effector molecules including cytokines, growth
factors, chemokines adhesion molecules, and enzymes [65]. Several in vitro and in vivo studies have
evaluated the role of flavonoids on DN, most of them reporting a positive effect on renal function,
evidenced by reduced levels of serum creatinine and urine albumin [66,67]. For example, in a rat model
of STZ-induced DN combined with high-fat, high-carbohydrate diet, the treatment with mangiferin
extracted from Pyrrosiae folium down-regulated IL-6, TNF-α and IL-1β expression and improved
renal pathological damage [67]. Similarly, corn silk extract, liquiritigenin and naringin also exhibited
anti-inflammatory activity by reducing the expression of IL-1β and IL-18 in mesangial cells exposed to
high glucose conditions [68–70].
In diabetic kidney, high levels of glucose and other metabolites, including inflammatory cytokines
and free fatty acids, lead to an excessive ROS production, being Nox and mitochondrial dysfunction the
main sources of ROS generation [71]. It has been demonstrated that ROS promote serine phosphorylation
of insulin receptor and insulin receptor substrate through different pathways inducing insulin signaling
suppression [72]. Moreover, overproduction of ROS modulates activation of PKC, mitogen-activated
protein kinases (MAPK), and several transcription factors and cytokines responsible of the inflammatory
response and extracellular matrix accumulation with further progression to ESRD [71].
A number of studies have described the renal antioxidant effects of several flavonoids. Formonetin
reduced oxidative stress burden and attenuated kidney damage in a T2D rat model by increasing the
activity of the antioxidant enzymes SOD and CAT, along with induction of the protective molecule
Sirtuin-1 [73]. Diosmetin, a flavonoid extracted from the leaves of Olea europaea with strong antioxidant
property, restored the reduced levels of SOD and NO observed in the kidney of diabetic rats and
decreased the levels of malondialdehyde (MDA), a lipid peroxidation marker [66]. The flavanone
naringin also attenuates ROS production in diabetic kidneys with concomitant reduction in Nox4
expression and increase in antioxidant enzymes SOD and GPx [74]. In vitro experiments have also
demonstrated that the strong anti-oxidant effect of different flavonoids (e.g., corn silk extracts and
liquiritigenin) is linked to Nox4 inhibition and SOD induction [68,69,75].
AGEs could accumulate in glomerular basement membrane, podocytes, endothelial cells and
mesangial cells in diabetic patients compromising renal function through different mechanisms, such as
oxidative stress, chronic inflammation and fibrosis. Therefore, the blockade of AGEs and their receptor
system (RAGEs) as well as downstream related pathways has become another therapeutic target for the
treatment of DN [76]. In this regard, the protective effect of kaempferitrin was evaluated in glomerular
mesangial cells exposed to AGEs [75]. In this study, kaempferitrin reduced AGE-induced oxidative
stress by increasing SOD activity and by reducing MDA levels and ROS generation. Moreover, this
flavonoid prevented the increase in collagen IV and TGF-β1 levels [75]. The anti-fibrotic effect has
also been demonstrated by other flavonoids such as chrysin which inhibited AGEs-induced expression
of collagens, and matrix metalloproteinases in mesangial cells and prevented collagen and AGEs
accumulation in diabetic kidneys from the db/db mouse model of T2D [77].
The polyphenolic natural product resveratrol though described as a non-flavonoid compound, also
reduced AGE levels in kidneys, attenuating the progression of DN [78].
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5.2. Diabetic Retinopathy
Diabetic retinopathy (DR) is a complication of diabetes affecting the eye that may cause severe
vision loss and blindness. High glucose levels are associated with damage to the vasculature of retina.
Diabetic macular edema is a consequence of DR that causes swelling in the area of the retina called the
macula [79].
Several studies have assessed the potential benefits of flavonoids on eye affectation during
diabetes. Most of them have shown the antioxidant, anti-inflammatory and anti-angiogenic effect
exerted by flavonoids in the eye, leading to an improvement in DR. For example, catechin inactivated
the NF-κB signaling pathway and reduced the expression of downstream target genes (e.g., IL-1β,
IL-6, and TNF-α) in the retina of STZ-induced diabetic rats [80]. Biochanin A showed a dual action on
inflammation and angiogenesis in a type 1 diabetic rat model, associated with decreased expression of
TNF-α, IL-1β and VEGF in the retina [81]. Similarly, administration of morus alba extract [82] or the
flavanone naringenin [83] attenuated oxidative, apoptotic, angiogenic and neurodegenerative markers,
whereas gallangin [84] attenuated inflammation and blood–retinal barrier breakdown in diabetic rats.
An in vitro study performed in human retinal capillary endothelial cells exposed to high glucose
concentrations demonstrated that blueberry anthocyanin extracts reduced VEGF by inhibiting the Akt
pathway. This anti-angiogenic effect was accompanied by an improvement in the oxidative and
inflammatory state, evidenced by increased antioxidant enzymes (SOD and CAT) and reduced pro-oxidant
enzymes (Nox4 and eNOS) and NF-κB activity [85]. Moreover, anti-inflammatory and anti-oxidant
effects have also been demonstrated by myricetin, eriodyctiol and galangin in retinal epithelial, ganglial and
microglial cells, respectively [84,86,87]. In addition, baicalin protects human retinal pigment epithelial cells
against hyperglycemic conditions by reducing the proliferative, anti-apoptotic and anti-inflammatory
effects by up-regulation of miR-145 and further inhibition of NF-κB and p38 MAPK pathways [88].
Kang et al. demonstrated that chrysin ameliorated the malfunction of the retinoid visual cycle by
increasing retinoid binding proteins (RPE65, LRAT, RDH5, and rhodopsin), downregulating angiogenic
factors, and blocking AGE-induced endoplasmic reticulum stress in glucose-stimulated RPE cells and
diabetic retina of db/db mice [89].
5.3. Diabetic Neuropathy
Diabetic neuropathy is a peripheral nerve disorder that affects organs which are innervated
by the autonomic nervous system like heart, eyes, gastrointestinal tract, kidney, and liver. Diabetic
neuropathy affects more than 50% of all diabetic patients and is commonly associated with loss of
sensation in the feet leading to difficulty to walk and weakness in the foot muscles [90]. Oxidative stress
and inflammation play a central role in neuronal degeneration. Oxidative stress leads to activation
of inflammatory and apoptotic pathways resulting in insufficiency of neurochemical growth factors,
neurovascular dysfunction, demyelination of neurons and increased autoimmune damage [91,92].
Therefore, the inhibition of oxidative stress and inflammation cascades could be an option to prevent
the development of diabetic neuropathy.
Several examples of the protective actions of flavonoids against diabetic neuropathy have been
published. Catechin, in a model of STZ-diabetic induced rats, was able to reduce the neuronal damage by
increasing SOD and CAT, and reducing MDA and lymphocyte infiltration in nerve tissues [93]. Deguelin
also ameliorates diabetic neuropathy, attenuated oxidative stress and neuroinflammation through the
activation of NRF2 pathway, and partially restored the conduction velocities of neurons in diabetic
rats by increasing (Na+-K+) ATPase activity [94]. A similar neuroprotective effect against oxidative
stress and inflammation was reported for phloretin, which either alone or in combination with the
anti-neuropathic agent duloxetine promoted nerve fiber regeneration in STZ-induced diabetic rats [95].
A study performed to assess the role of resveratrol in diabetic neuropathy showed that it
provides neuroprotection by increasing SOD and reducing GSH and inhibiting nitrosative stress
and myeloperoxidase (MPO) activity in diabetic rats [96]. Likewise, quercetin in combination with
moderate exercise training attenuated neuropathy and restored histological alterations in sciatic
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nerves in STZ-diabetic rats through antioxidant enzyme induction and down-regulation of free
radical production [97]. In vitro experiments revealed that inhibition of NF-κB and activation
of NRF2/Heme-oxygenase-1 (HO-1) signaling pathways contribute to the anti-inflammatory and
antioxidant effects of quercetin, cinnamaldehyde and hirudin in dorsal root ganglion neurons exposed
to high glucose [98,99]. Similarly, puerarin inhibited oxidative stress and apoptosis induced by
hyperglycemia in Schwann cells via suppression of caspase-3 cascade [100].
5.4. Diabetic Macrovascular Complications
Macrovascular manifestations of diabetes include primarily diseases of the coronary and peripheral
arteries, leading to cardiovascular events. Early macrovascular disease is associated with atherosclerotic
plaque in the vessels that supply blood to the heart, brain, limbs, and other organs, whereas late stages
of macrovascular disease involve complete arterial obstruction whit an increased risk of myocardial
infarction and stroke [15].
It is well known that DM increases cardiovascular morbidity and mortality. However, surprisingly
in the last years, the role of flavonoids on cardiovascular complications associated with DM has been
poorly studied compared to other diabetic complications such as retinopathy or nephropathy. Most of
the studies are focused on assessing the role of flavonoids on endothelial dysfunction since it is one of
the earliest and most prevalent abnormalities of cardiovascular complications associated with DM [101].
Bharat et al. tested the possible beneficial effect of blueberry anthocyanins in human aortic endothelial
cells exposed to palmitic acid. The authors found that anthocyanins attenuated endothelial dysfunction
through the suppression of Nox-mediated ROS production [102]. Rutin also prevented endothelial
dysfunction under hyperglycemic conditions both in vitro (human umbilical vein endothelial cells)
and in vivo (carbohydrate diet-treated rats), through inhibiting Nox4-mediated ROS generation and
NLRP3 inflammasome activation [103].
In a mouse model of T2D, liquiritigenin attenuated cardiac injury through its anti-fibrotic and
anti-inflammatory effect by inactivating NF-κB signaling pathway [104]. Likewise, apigenin protected
from cardiovascular damage by preventing cardiomyocyte hypertrophy and fibrosis and attenuating
oxidative and inflammatory state in experimental T1D [105].
Resveratrol was able to reduce ROS production in human aortic endothelial cells through the
modulation of autophagy as a result of AMPK-mTOR pathway regulation [106] and also exhibited
cardioprotective effects in vivo, as it restored the disruption and thickening of the muscle fibers
in a diabetic rat model with coronary heart disease [107]. Moreover, resveratrol in combination with
glibenclamide was able to reduce ischemia/reperfusion induced arrhythmias in a diabetic rat model [108].
On the other hand, lipid alterations are very common in patients with diabetes, mainly among
those who have T2D. It is well known that there is a close relation between hyperlipidemia and the
outcome of cardiovascular events in the context of diabetes. Specifically, alterations on the lipid
profile can eventually result in atherosclerosis [109]. Therefore, an adequate control of lipid levels
is necessary to prevent diabetic complications. Considering the relevance of flavonoids in recent
years in the study of diabetes, it is not surprising the existence of numerous studies confirming the
anti-hyperlipidemic effect of these compounds. In this sense, a study performed by Mohammed
Yusof demonstrated that Hibiscus sabdariffa (roselle) polyphenol-rich extract, including anthocyanidins,
acts as a cardioprotective agent by lowering total cholesterol, triglyceride and LDL and increasing
HDL [110]. Likewise, isoquercertin [111] and galangin [112] have been shown to decrease triglycerides,
phospholipids and free fatty acids in diabetic rats, whereas scutellarin alleviated dyslipidemia in db/db
mice by increasing HDL and reducing triglycerides and total cholesterol [113].
6. Clinical Studies on Flavonoids in Diabetes
In contrast to the extensive experimental research in various models of diabetic complications, a
limited number of published clinical studies of flavonoids in diabetic patients are available (Tables 2
and 3).
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Table 2. Summary of the Completed Clinical Trials with Flavonoids for the Treatment of DM.












Renoprotective effect of milk thistle
extract on T2D patients with
macroalbuminuria.
n = 30; 3 × 140 mg silymarin
n = 30; Placebo 3 months
Significant decrease in UACR levels, urinary TNF-α
and urinary and serum MDA in the silymarin group.
22770926
NCT01003236
Effect of silymarin on glycemic control
and body mass index in T2D patients
with insulin resistance and poor glycemic
control with oral hypoglycemic agents
n = 18; 200 mg silymarin + 10
mg Glibenclamide
n = 21; Placebo + 10mg
Glibenclamide
4 months
Silymarin treatment significantly reduced fasting and
postprandial plasma glucose, HbA1c levels and body
mass index.
17887949
Effects silymarin administration on the
glycemic state in T2D patients.
n = 25; 3 × 200 mg silymarin
n = 26; Placebo 4 months
Decreased significantly FBG, HbA1c, total cholesterol,
LDL, triglyceride, GOT and GPT after treatment with
silymarin.
17072885
Safety and effect of green tea
(epigallocatechin gallate, EGCG) in
patients with DN.
n = 24; ACEi/ARBs + 800 mg
EGCG
n = 23; ACEi/ARBs + Placebo
3 months Treatment with green tea extract reduced UACR by41%.
27320846
NCT01923597
Effects of isolated soy protein
consumption on urinary albumin
excretion and blood lipid profile in early
stages of DN.
n = 14; 0.5 g/kg/day of the
dietary protein was provided as
either isolated soy protein
2 × 8 weeks Soy protein consumption reduced UACR levels by9,55%. 15284369
Efficacy of curcumin for blocking DN
development in T2D patients (short
time).
n = 14; 500 mg curcumin 1 month
Curcumin attenuated microalbuminuria and reduced
plasma MDA and LPS levels content. Maintaining gut













Effects of pycnogenol in early stages of
DR.
n = 24; 150 mg pycnogenol
n = 22; Placebo 2 months
Visual improvement was subjectively perceived by 18
of 24 patients in the pycnogenol group. Significant
improvement visual acuity from baseline.
19916788
Evaluate long-term follow-up of the
orally administered combination of
flavonoids for treatment of diabetic
cystoid macular edema without macular
thickening.
n = 35; 300 mg Diosmin,
15 mg C. asiatica
160 mg Melilotus
n = 35; Placebo
3 years
Retinal sensitivity reduced in control group only from
month 6 until month 36. In the treatment group, a
greater retinal sensitivity was present at month 12, 24,
and 36.
23844756
Determine the relationship between
dietary flavonoid-rich fruit and
vegetable consumption on DM-related
biomarkers and DR.
Data from 381 participants with
DM from the NHANES
2003–2006.
-
Greater high-flavonoid fruit and vegetable
consumption was associated with lower levels of CRP,
HbA1c and glucose, with reducing the odds of having
diabetic retinopathy by 30%.
25055729
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Table 2. Cont.
Objective to Study Treatment Duration Results PMID
Efficacy of anti-oxidant dietary
supplementation reducing the ROS levels
in patients with non-proliferative DR.
n = 34; 50 mg pycnogenol, 30 mg
Vit. E, 20 mg CoQ
n = 34; Placebo
6 M
In the group receiving antioxidant therapy the levels
of free oxygen radicals and retinal thickness were
significantly reduced over three times. Conversely, in













Efficacy and safety of QR-333 (quercetin,
ascorbyl palmitate and vitamin D3) in
the treatment of diabetic neuropathy.
n = 23; three topical
applications QR-333
n = 11; Placebo
1 M
QR-333 produced significant relief of some symptoms



















Effect of flavanol-rich chocolate in
patients with hypertension.
n = 20; Cross-over
100 mg Dark Chocolate
(88 mg flavanols)




Dark chocolate decreased blood pressure and serum
LDL cholesterol, improved FMD, and ameliorated
insulin sensitivity in hypertensive patients.
16027246
Evaluate whether regular ingestion of an
unsweetened, strongly defatted and
flavanol-rich cocoa powder might
improve BP and glucose and lipid
metabolism in stably treated T2D
subjects.
n = 17; Five × 0.5 g cocoa powder
capsules
n = 18; Placebo
3 M
Daily intake of 2.5 g of flavanol-rich, unsweetened
and strongly defatted cocoa powder does not affect BP,
glucose and lipid metabolism in stably-treated
patients with T2D and hypertension in a fasting state.
30301127
Effect of dietary flavonoids on CVD risk
in postmenopausal women with T2D on
established statin and hypoglycemic




Improvement in insulin sensitivity was observed.
Reductions in total cholesterol, HDL-cholesterol ratio
and LDL cholesterol. Estimated 10 year total coronary
heart disease risk was attenuated after flavonoid
intervention. 22250063
NCT00677599
Effect of combined isoflavone and
flavan-3-ol intake on vascular function in
postmenopausal women with T2D.
The flavonoid intervention did not significantly
change the intima-media thickness of the common
carotid artery, augmentation index, or BP, but pulse
pressure variability improved.
Effect of oral Hesperidin
supplementation in hemodynamic
changes in T2D patients.
n = 32; 500 mg Hesperidin
n = 32; Placebo 1.5 M
Significant difference in mean percent change of SBP,
diastolic blood pressure, mean arterial BP, serum TAC,
and inflammatory markers between Hesperidin and
control groups.
29468764
Association between the intake of total
polyphenols and polyphenol classes with
the major CV risk factors in a T2D
population. TOSCA.IT study.
n = 2573 people with T2D 10 years
A diet characterized by a higher intake of total
polyphenols was associated with a better




J. Clin. Med. 2020, 9, 346 17 of 30
Table 3. Ongoing Clinical Trials of Flavonoids, Flavonoid-Rich Foods and Flavonoid-Rich Dietary Patterns Intervention in DM.
Title Design Objective Patients Treatment Duration
Green tea extract on Soluble




Evaluate effect of administration of green
tea extract on soluble RAGE and renal




400 mg green tea extract
vs. 400 mg placebo
3 months




Study the efficacy of fisetin on
stem/stromal cell function, kidney
function, inflammation and physical








to evaluate the efficacy and
safety of WH-1 ointment for the






Evaluate efficacy and safety of WH-1








alternate days or three
times a week
4 months
Metabolic Benefits of Drinking




Determine whether chronic consumption
of blueberry tea improve metabolic and




Three cups of blueberry
tea per day vs. non
treatment
1 month
Effects of Mediterranean Diet





Examine short-term effects of modified
Mediterranean diet on lipogenic




control diet 9 days
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6.1. Diabetic Nephropathy
Several studies have provided evidence supporting a beneficial effect of flavonoids, flavonoid-rich
foods and polyphenolic natural product on DN. To date, the main bioactive phytochemicals assayed in
clinical trials on DN are: silymarin, green tea extract, soy protein and curcumin. Fallahzadeh et al. [114]
evaluated the renoprotective effect of silymarin, an isomeric mixture of seven flavonolignans present
in milk thistle, in a randomized controlled double-blind trial in 60 patients with type 2 DN and
macroalbuminuria (urinary albumin excretion >300 mg/24 h). Administration of three daily tablets
(140 mg of silymarin each) for 3 months reduced urinary albumin-creatinine ratio (UACR), urinary
levels of TNF-α and urinary and serum levels of MDA. Silymarin also demonstrated to improve the
glycemic profile (reducing fasting blood glucose and HbA1c) when administered to diabetic patients
in addition to the standard treatment (hypoglycemic agent) [115,116].
Borges et al. [117] also evaluated the impact of green tea extract (epigallocatechin gallate) on the
UACR in T1D and T2D patients. Administration of four daily capsules of 200 mg of epigallocatechin
gallate to 24 patients for 3 months resulted in a significant decrease in UACR (41% of baseline). These
results are in accordance with the results obtained by Teixeira [118] and Yang [119], who also observed
a decrease in the UACR levels through administration of flavonoids in T2D patients. A later study
performed by Sattarinezhad [120] also showed a decrease in the UACR when administering resveratrol.
A meta-analysis performed by Liu et al. [121] showed the potential renal protective effects of breviscapine
(flavonoid of Erigeron breviscapus) injections, reducing urine protein, serum creatinine and blood urea
nitrogen in DN patients. Despite the progress in the flavonoids nephroprotection research, further
studies in larger cohorts, longer follow-up and more robust endpoints (e.g., glomerular filtration rate
and disease progression) are needed to assess the use of flavonoids as an add-on therapy to current
standard of care in DN.
6.2. Diabetic Retinopathy
The therapeutic role of flavonoids in DR has been evaluated in several clinical trials using mainly
pycnogenol and diosmin. Steigerwalt et al. [122] evaluated in 46 T2D patients with well controlled blood
glucose (HbA1c <7%) and early stages of DR the efficacy of pycnogenol to improve microcirculation,
retinal edema, and visual acuity. Subjects were daily treated with 3 × 50 mg pycnogenol or placebo
tablets for 2 months. Visual improvement was perceived in 18 of 24 patients in the pycnogenol group
and visual acuity significantly improved in the treated group. It was concluded that pycnogenol taken
at early stages of retinopathy may enhance retinal blood circulation accompanied by regression of
edema, which favorably improves patient vision. Forte et al. [123] evaluated, in 70 T2D patients
with diabetic cystoid macular edema (CME) without macular thickening, the long-term effects of
an oral pill containing 300 mg of Diosmin, 15 mg of Centella asiatica and 160 mg of Melilotus. They
concluded that oral administration of this combination provided preservation of retinal sensitivity
during the 36 months of follow up, when compared with untreated patients. Mahoney et al. [124]
evaluated the influence of dietary flavonoids in data of 381 diabetic patients from the National Health
and Nutrition Examination Survey (NHANES from 2003 to 2006). C-reactive protein, HbA1C, fasting
glucose and insulin were measured in blood samples and a retinal imaging exam was done to assess
DR. A high-flavonoid fruit and vegetable consumption index was created from a food frequency
questionnaire and it was concluded that diabetic adults had lower degrees of inflammation, better
glycemic control, and reduced odds of diabetic retinopathy when consuming more flavonoids in the
diet. Domanico et al. [125] evaluated the changes in circulating levels of ROS and central macular
thickening in 68 patients with non-proliferative diabetic nephropathy. One daily tablet containing
50 mg of pycnogenol, 30 mg of vitamin E and 20 mg of coenzyme Q10 was administered for 6 months and
the blood levels of ROS were determined using the free oxygen radical test. A significant decrease in the
free radical levels of the patients receiving the anti-oxidant therapy was observed, whereas a significant
increase occurred in the control group. The central macular thickening was significantly reduced in the
treated group, whereas no significant changes were found in the control group. A review made by
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Zhang et al. [126], analyzed studies published up to June 2018 that evaluated the effectiveness and safety
of single herbal medicine in DR. They included randomized controlled trials and quasi-randomized
trials that investigated the effects of any single herb (or extracts from a single herb) as a treatment for
people with DR. The authors could not draw conclusions about the effect of any single herb or herbal
extract on DR from the current available evidence due to the lack of placebo control group. Therefore,
further adequately designed trials are needed to establish the evidence.
6.3. Diabetic Neuropathy
In diabetic neuropathy, the only flavonoids that have been studied are quercetin and puerarin.
Valensi et al. [127] evaluated in a proof-of-concept study the effect of a topical compound containing
quercetin in 34 patients. The primary objective was to decrease the oxidative stress that contributes
to peripheral diabetic neuropathy and thus to alleviate the symptoms. The compound appeared to
have certain effects, offering relief of diabetic neuropathy symptoms and improving quality of life.
Subsequently, they performed a bigger trial [127], where this effect was further studied, but no results
were published. Wu et al. [128] made a systematic review and meta-analysis of randomized controlled
trials involving efficacy and safety of puerarin injection in treatment of diabetic peripheral neuropathy.
The authors included 22 low-quality studies involving 1664 participants. Puerarin was effective and
safe for the treatment of diabetic peripheral neuropathy. However, since the articles included in the
study were not of high-quality, more studies should be conducted to strengthen their findings. Zheng
et al. [129] reviewed the therapeutic efficacy of combined therapy of diabetic peripheral neuropathy
with breviscapine and mecobalamine, an endogenous coenzyme B12. They analyzed 17 studies with
a total of 1398 patients including 718 treated with breviscapine and mecobalamin and 680 treated
with mecobalamin alone. In these studies, patients received diet control, physical exercise, and
glucose-lowering therapy before interventions. This meta-analysis suggests that the combined therapy
is safe and effective for these patients, although more high-quality, controlled, randomized clinical
trials are needed for further confirmation.
6.4. Cardiovascular Complications
Early research [130,131] provided some evidence that cocoa products, which have a high content of
flavonoids, may contribute to cardiovascular protection. Accordingly, a recent review by Ried et al. [132]
afforded evidence for the blood pressure-lowering effect of flavanol-rich chocolate and cocoa products.
Dicks et al. investigated whether regular ingestion of 2.5 g/day of flavanol-rich cocoa powder, in addition
to their standard medication, might affect blood pressure as well as glucose and lipid metabolism in
42 stable treated subjects with T2D. They did not see any improvement in cardiometabolic parameters
and attributed this finding to the fact that antihypertensive medication and cocoa flavonols could
modulate partly the same targets. Therefore, they outlined the need of new studies focusing on the
preventive effect of cocoa against diabetes and other cardiometabolic diseases in individuals with
preexisting abnormalities that do not require any pharmacological treatment. Curtis et al. [133–135]
evaluated the effect of 1 year therapy with flavonoids, in addition to statin-therapy, on cardiovascular
risk reduction in postmenopausal women with T2D, and concluded that long-term flavan-3-ol and
isoflavone intakes may improve markers of arterial stiffness and aspects of hemodynamic function in
T2D patients taking established medication. However, additional studies are required to confirm this
theory. Homayouni et al. [136] carried out a clinical trial on 64 T2D patients to study the blood pressure
lowering and anti-inflammatory effects of Hesperidin (500 mg/day) administered for 6 weeks. Data on
blood pressure and anti-inflammatory markers was recorded. The hesperidin group, but not the control
group, had a significant reduction in systolic blood pressure and mean arterial blood pressure after the
intervention period and the level of IL-6 and TNF-α were significantly reduced. The Thiazolidinediones
Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study analyzed the dietary
habits of 2573 participants with T2D [137]. Anthropometric measures, plasma lipids, blood pressure,
C-reactive protein and HbA1c levels were measured. It was concluded that a diet characterized by a
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higher intake of total polyphenols was associated with a better cardiovascular risk factors profile and a
lower grade of subclinical inflammation.
7. Ongoing Clinical Trials
A search in clinicaltrials.gov and in the AdisInsight database was done to analyze ongoing clinical
trials related with Flavonoids and Diabetes. Only five trials were found (Table 3). Among them, the
only diabetic complication approached was DN.
One of the studies [138] will evaluate the effects of green tea extract on RAGEs in T2D patients
with DN. Thirty patients will receive 400 mg of tea extract or placebo twice a day during 12 weeks
and soluble RAGEs and renal damage will be evaluated through the measure of the following
parameters: soluble RAGE concentration, glomerular filtration rate, albumin/creatinine ratio, fasting
plasma glucose, Hb1Ac concentration, systolic and diastolic arterial pressure, alanine aminotransferase,
aspartate aminotransferase, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, weight
and visceral fat. Another study [139] evaluates the efficacy of fisetin on stem cells in 30 patients with
diabetic kidney disease. Fisetin will be administered for two consecutive days vs. placebo and the
efficacy on adipose tissue-derived mesenchymal stem/stromal cell function, kidney function (eGFR,
UACR), markers of inflammation (C-reactive protein), and physical function in individuals with
advanced chronic kidney disease will be tested. Other study is also evaluating the role of flavonoids
on diabetic foot ulcers [140]. Furthermore, a 4 week interventional study is planned to evaluate the
metabolic benefits of drinking three daily cups of blueberry tea in 36 T2D patients [141]. Also, a study
to evaluate the effects of Mediterranean diet before coronary artery by-pass grafting surgery [142] is
going to be performed on 48 patients with T2D.
There are also two observational studies planned [143,144], with a follow-up period higher than
10 years, that will study the appearance of different clinical conditions, for example DM and metabolic
syndrome, and try to correlate them with their risk factors. In brief, although there are some ongoing
clinical trials, there is still a lack of trials targeted to investigate the possible beneficial effect of different
therapeutic strategies based on flavonoids in diabetic complications. Moreover, there are some clinically
unexplored diabetic complications where flavonoids could be beneficial.
8. Toxicity and Adverse Effects of Flavonoids
Although most flavonoids, flavonoid-rich foods, flavonoid-rich dietary patterns and phenolic compounds
are considered safe, there have been studies of toxic flavonoid-drugs interactions, liver failure, contact
dermatitis, hemolytic anemia and estrogenic-related concerns, among others [145]. In this regard,
Alkhalidy et al. mentioned some studies where flavonoids, in the presence of copper, may become
pro-oxidant as well as the potential mutagenicity of quercetin after long-term intake [51]. The authors
also suggest that flavonoids should not be given in large quantities until their biological and potential
adverse effects are clarified. The studies of Bugel et al., using a zebrafish embryo-larval toxicity
bioassay, also showed adverse effects on early embryogenesis of some flavonoids and flavonoid-like
chemicals [146]. Therefore, the potential harmful effects of certain flavonoids should be considered by
pharmaceutical companies at the time of preclinical validation both in vitro and in vivo.
One of the major problems of bringing flavonoids to the market is, in general, its poor availability.
This information has been gathered mainly with flavonoids contained in many foods. Due to the great
variability of flavonoids and phenolic compounds, each of them should be evaluated when planning
its development for clinical use. Among the different strategies designed with the aim of optimizing
the solubility and bioavailability of flavonoids, novel strategies are needed [147,148]. In this regard, the
application of flavonoids through nanoparticles and nanodelivery has been considered in DM [149].
9. Future Perspectives and Conclusions
This comprehensive review addresses, from an objective point of view, the current state of the art
about the preclinical and clinical use of flavonoids in tissue-specific manifestations of DM. As from the
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year 2000, the number of published studies regarding the therapeutic application of flavonoids has
been exponential. There is extensive evidence of the anti-diabetic effects of flavonoids, mainly based
on the local modulation of the inflammatory, oxidative and lipotoxic microenvironment leading to a
protective effect in the tissue and organs affected by DM (Figure 3).
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DM is a current globa epid mic disease and, despite the fact that urrent the apies have facilitated
a better control of the disease, few are the th rapi s aiming to regulate local infl mmatory and oxidative
stress. Potentially, the introduction of nutraceuticals into clinical practice could have an added value in
reducing or retarding the micro or macrovascular complications associated with DM and therefore
the direct and indirect health costs devoted to these patients. One of the great difficulties described
for the clinical application of flavonoids refers to the low scientific evidence regarding the in vivo
biodistribution and pharmacokinetic parameters of these compounds. Additionally, because the
complications of DM are characterized by a slow and insidious development, the preclinical assessment
of its therapeutic effects becomes even more complex.
The current technological development in the pharmaceutical industry predicts a promising
future of the use of flavonoids in inflammatory based diseases, increasing the purity percentage of
compounds, optimizing their formulation in order to obtain greater stabilization in vivo and target
tissue bioavailability, thus prolonging their therapeutic effect.
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In brief, we provide updated information concerning the discrepancy between the numerous
experimental studies supporting the efficacy of flavonoids on diabetic complications and the lack
of appropriate and well-designed clinical trials. Due to the well-described beneficial effects on
different mechanisms involved in diabetic complications, the excellent tolerability and low cost, future
randomized controlled studies with compounds that have adequate bioavailability should be evaluated
as add-on therapy on well-established anti-diabetic drugs.
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